Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer.

Trial Profile

A Randomized, Open-Label, Parallel-Group, Multicentre, Phase II Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX) 500 mg With Anastrozole (ARIMIDEX) 1 mg as First Line Hormonal Treatment for Postmenopausal Women With Hormone Receptor Positive Advanced Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Acronyms FIRST
  • Sponsors AstraZeneca
  • Most Recent Events

    • 14 Nov 2018 Results assessing the effectiveness and cost of fulvestrant versus anastrozole from FIRST and FALCON trials, presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 09 Dec 2017 Results of FALCON, FIRST and CONFIRM studies comparing treatment effect of Fulvestrant vs comparators in post-menopausal patients, presented at the 40th Annual San Antonio Breast Cancer Symposium.
    • 01 Feb 2017 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top